Cangene appoints new CEO

Cangene Corporation, a biopharmaceutical company primarily focused on specialty plasma products such as an anthrax immune globulin, has announced the appointment of John A. Sedor Tuesday as president and chief executive officer.
The company's board of directors unanimously appointed Sedor, who will join Cangene on September 12. Michael Graham, Cangene's chief financial officer, has been serving as interim president and CEO and will continue in his role as CFO.
"John's appointment is the culmination of a rigorous and thoughtful search process over the past six months," Craig Baxter, the board chair for Cangene, said. "We believe he is the ideal CEO for the company. He is a visionary leader and strong manager who brings a successful track record of growing companies and efficiently managing them to create value for shareholders, customers, partners and employees. We look forward to his leadership as we work together to build on our platform and start a new, exciting chapter at Cangene."
Sedor has more than 30 years of leadership experience in the global biopharmaceutical, generic drug and consumer product industries. He most recently served as president, CEO and director of CPEX Pharmaceuticals, Inc.
"I'm very pleased to join Cangene, a pioneering company with solid fundamentals, including successful biodefense and biopharma products, a strong balance sheet and talented people," Sedor said. "Over the next few months, I intend to conduct a comprehensive, top-to-bottom review of the business and develop a plan to accelerate growth and enhance shareholder value at Cangene. I believe this company has significant value-creation potential and intend to drive it to achieve that potential over the long-term."
In addition to the anthrax immune globulin, Cangene is also investigating a botulism antitoxin and a vaccine immune globulin that may be used to counteract certain smallpox vaccination complications.